Download PDF
Semin Respir Crit Care Med 2011; 32(5): 598-606
DOI: 10.1055/s-0031-1287869
© Thieme Medical Publishers

Cardiovascular Failure and Cardiogenic Shock

Ankitkumar K. Patel1 , Steven M. Hollenberg1
  • 1Cardiology and Critical Care Medicine, Cooper University Hospital, Camden, New Jersey
Further Information

Publication History

Publication Date:
11 October 2011 (online)

    Permissions and Reprints

ABSTRACT

Cardiovascular system failure is commonly faced by the intensivist. Heart failure can occur due to a host of predisposing cardiac disorders or as secondary effects of systemic illness. When the heart is unable to provide an adequate cardiac output to maintain adequate tissue perfusion, cardiogenic shock ensues. Without prompt diagnosis and appropriate management, these patients have significant morbidity and mortality, with in-hospital mortality approaching 60% for all age groups. Accurate and rapid identification of cardiogenic shock as a medical emergency, with expeditious implementation of appropriate therapy, can lead to improved clinical outcomes. In this review, we discuss optimal strategies for diagnosis and monitoring of cardiogenic shock. We discuss the diverse therapeutic strategies employed for cardiogenic shock, including pharmacological (e.g., vasoactive agents, fibrinolytic agents), mechanical (e.g., intraaortic balloon pumps, left ventricular assist devices, percutaneous coronary intervention [PCI]), and surgical approaches such as coronary artery bypass graft (CABG), valvular repair or replacement (e.g., for acute mitral regurgitation, ventricular septal rupture, or free wall rupture).

KEYWORDS

Cardiogenic shock - intensive care - myocardial infarction - echocardiography - right heart catheterization - vasopressor therapy - inotropic therapy

REFERENCES

  • 1 Sarswat N, Hollenberg S M. Cardiogenic shock.  Hosp Pract (Minneap). 2010;  38 (1) 74-83
    CrossrefPubMedGoogle Scholar
  • 2 Hochman J S, Boland J, Sleeper L A SHOCK Registry Investigators et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an international registry.  Circulation. 1995;  91 (3) 873-881
    CrossrefPubMedGoogle Scholar
  • 3 Goldberg R J, Spencer F A, Gore J M, Lessard D, Yarzebski J. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective.  Circulation. 2009;  119 (9) 1211-1219
    CrossrefPubMedGoogle Scholar
  • 4 Hollenberg S M, Kavinsky C J, Parrillo J E. Cardiogenic shock.  Ann Intern Med. 1999;  131 (1) 47-59
    PubMedGoogle Scholar
  • 5 Hollenberg S M. Recognition and treatment of cardiogenic shock.  Semin Respir Crit Care Med. 2004;  25 (6) 661-671
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Hochman J S, Boland J, Sleeper L A SHOCK Registry Investigators et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an international registry.  Circulation. 1995;  91 (3) 873-881
    CrossrefPubMedGoogle Scholar
  • 7 Holmes Jr D R, Bates E R, Kleiman N S et al.. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.  J Am Coll Cardiol. 1995;  26 (3) 668-674
    CrossrefPubMedGoogle Scholar
  • 8 Hollenberg S M, Kavinsky C J, Parrillo J E. Cardiogenic shock.  Ann Intern Med. 1999;  131 (1) 47-59
    PubMedGoogle Scholar
  • 9 Hochman J S. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm.  Circulation. 2003;  107 (24) 2998-3002
    CrossrefPubMedGoogle Scholar
  • 10 Picard M H, Davidoff R, Sleeper L A SHOCK Trial. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.  Circulation. 2003;  107 (2) 279-284
    CrossrefPubMedGoogle Scholar
  • 11 Kohsaka S, Menon V, Lowe A M SHOCK Investigators et al. Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock.  Arch Intern Med. 2005;  165 (14) 1643-1650
    CrossrefPubMedGoogle Scholar
  • 12 Jeger R V, Assmann S F, Yehudai L, Ramanathan K, Farkouh M E, Hochman J S. Causes of death and re-hospitalization in cardiogenic shock.  Acute Card Care. 2007;  9 (1) 25-33
    CrossrefPubMedGoogle Scholar
  • 13 Bolli R. Basic and clinical aspects of myocardial stunning.  Prog Cardiovasc Dis. 1998;  40 (6) 477-516
    CrossrefPubMedGoogle Scholar
  • 14 Gerber B L, Wijns W, Vanoverschelde J L et al.. Myocardial perfusion and oxygen consumption in reperfused noninfarcted dysfunctional myocardium after unstable angina: direct evidence for myocardial stunning in humans.  J Am Coll Cardiol. 1999;  34 (7) 1939-1946
    CrossrefPubMedGoogle Scholar
  • 15 Wijns W, Vatner S F, Camici P G. Hibernating myocardium.  N Engl J Med. 1998;  339 (3) 173-181
    CrossrefPubMedGoogle Scholar
  • 16 Kloner R A, Jennings R B. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 1.  Circulation. 2001;  104 (24) 2981-2989
    CrossrefPubMedGoogle Scholar
  • 17 Korewicki J. Cardiac transplantation is still the method of choice in the treatment of patients with severe heart failure.  Cardiol J. 2009;  16 (6) 493-499
    PubMedGoogle Scholar
  • 18 Rose E A, Gelijns A C, Moskowitz A J Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group et al. Long-term use of a left ventricular assist device for end-stage heart failure.  N Engl J Med. 2001;  345 (20) 1435-1443
    CrossrefPubMedGoogle Scholar
  • 19 Selman L, Harding R, Beynon T et al.. Improving end-of-life care for patients with chronic heart failure: “let's hope it'll get better, when I know in my heart of hearts it won't”.  Heart. 2007;  93 (8) 963-967
    CrossrefPubMedGoogle Scholar
  • 20 McCarthy III R E, Boehmer J P, Hruban R H et al.. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis.  N Engl J Med. 2000;  342 (10) 690-695
    CrossrefPubMedGoogle Scholar
  • 21 Gupta S, Markham D W, Drazner M H, Mammen P P. Fulminant myocarditis.  Nat Clin Pract Cardiovasc Med. 2008;  5 (11) 693-706
    CrossrefPubMedGoogle Scholar
  • 22 Klein R M, Vester E G, Brehm M U et al.. [Inflammation of the myocardium as an arrhythmia trigger].  Z Kardiol. 2000;  89 (Suppl 3) 24-35
    PubMedGoogle Scholar
  • 23 Cooper Jr L T. Myocarditis.  N Engl J Med. 2009;  360 (15) 1526-1538
    CrossrefPubMedGoogle Scholar
  • 24 Wittstein I S, Thiemann D R, Lima J A et al.. Neurohumoral features of myocardial stunning due to sudden emotional stress.  N Engl J Med. 2005;  352 (6) 539-548
    CrossrefPubMedGoogle Scholar
  • 25 Movahed M R. Important echocardiographic features of takotsubo or stress-induced cardiomyopathy that can aid early diagnosis.  JACC Cardiovasc Imaging. 2010;  3 (11) 1200-1201 author reply 1201
    CrossrefPubMedGoogle Scholar
  • 26 Huffman C, Wagman G, Fudim M, Zolty R, Vittorio T. Reversible cardiomyopathies—a review.  Transplant Proc. 2010;  42 (9) 3673-3678
    CrossrefPubMedGoogle Scholar
  • 27 Filsoufi F, Salzberg S P, Adams D H. Current management of ischemic mitral regurgitation.  Mt Sinai J Med. 2005;  72 (2) 105-115
    PubMedGoogle Scholar
  • 28 Filsoufi F, Rahmanian P B, Anyanwu A, Adams D H. Physiologic basis for the surgical treatment of ischemic mitral regurgitation.  Am Heart Hosp J. 2006;  4 (4) 261-268
    CrossrefPubMedGoogle Scholar
  • 29 Choudhry N K, Etchells E E. The rational clinical examination. Does this patient have aortic regurgitation?.  JAMA. 1999;  281 (23) 2231-2238
    CrossrefPubMedGoogle Scholar
  • 30 Morganroth J, Perloff J K, Zeldis S M, Dunkman W B. Acute severe aortic regurgitation: pathophysiology, clinical recognition, and management.  Ann Intern Med. 1977;  87 (2) 223-232
    PubMedGoogle Scholar
  • 31 Nohria A, Tsang S W, Fang J C et al.. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure.  J Am Coll Cardiol. 2003;  41 (10) 1797-1804
    CrossrefPubMedGoogle Scholar
  • 32 de Denus S, Pharand C, Williamson D R. Brain natriuretic peptide in the management of heart failure: the versatile neurohormone.  Chest. 2004;  125 (2) 652-668
    CrossrefPubMedGoogle Scholar
  • 33 Maisel A S, Krishnaswamy P, Nowak R M Breathing Not Properly Multinational Study Investigators et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.  N Engl J Med. 2002;  347 (3) 161-167
    CrossrefPubMedGoogle Scholar
  • 34 Logeart D, Saudubray C, Beyne P et al.. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea.  J Am Coll Cardiol. 2002;  40 (10) 1794-1800
    CrossrefPubMedGoogle Scholar
  • 35 Antman E M, Hand M, Armstrong P W Canadian Cardiovascular Society et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.  J Am Coll Cardiol. 2008;  51 (2) 210-247
    CrossrefPubMedGoogle Scholar
  • 36 Hochman J S, Sleeper L A, Webb J G et al.. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.  N Engl J Med. 1999;  341 (9) 625-634
    CrossrefPubMedGoogle Scholar
  • 37 Menon V, Slater J N, White H D, Sleeper L A, Cocke T, Hochman J S. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry.  Am J Med. 2000;  108 (5) 374-380
    CrossrefPubMedGoogle Scholar
  • 38 Forrester J S, Diamond G, Chatterjee K, Swan H JC. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts).  N Engl J Med. 1976;  295 (25) 1404-1413
    CrossrefPubMedGoogle Scholar
  • 39 De Backer D, Biston P, Devriendt J SOAP II Investigators et al. Comparison of dopamine and norepinephrine in the treatment of shock.  N Engl J Med. 2010;  362 (9) 779-789
    CrossrefPubMedGoogle Scholar
  • 40 Antman E M, Anbe D T, Armstrong P W American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction).  Circulation. 2004;  110 (5) 588-636
    CrossrefPubMedGoogle Scholar
  • 41 Felker G M, Benza R L, Chandler A B OPTIME-CHF Investigators et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.  J Am Coll Cardiol. 2003;  41 (6) 997-1003
    CrossrefPubMedGoogle Scholar
  • 42 Elahi M M, Lam J, Asopa S, Matata B M. Levosimendan Versus an Intra-aortic Balloon Pump in Adult Cardiac Surgery Patients With Low Cardiac Output.  J Cardiothorac Vasc Anesth. 2011 Mar 2. [Epub ahead of print] No abstract available
    PubMedGoogle Scholar
  • 43 Russ M A, Prondzinsky R, Christoph A et al.. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock.  Crit Care Med. 2007;  35 (12) 2732-2739
    CrossrefPubMedGoogle Scholar
  • 44 García-González M J, Domínguez-Rodríguez A, Ferrer-Hita J J, Abreu-González P, Muñoz M B. Cardiogenic shock after primary percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics.  Eur J Heart Fail. 2006;  8 (7) 723-728
    CrossrefPubMedGoogle Scholar
  • 45 Mebazaa A, Nieminen M S, Packer M SURVIVE Investigators et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.  JAMA. 2007;  297 (17) 1883-1891
    CrossrefPubMedGoogle Scholar
  • 46 Bates E R, Stomel R J, Hochman J S, Ohman E M. The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock.  Int J Cardiol. 1998;  65 (Suppl 1) S37-S42
    CrossrefPubMedGoogle Scholar
  • 47 Barron H V, Every N R, Parsons L S Investigators in the National Registry of Myocardial Infarction 2 et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2.  Am Heart J. 2001;  141 (6) 933-939
    CrossrefPubMedGoogle Scholar
  • 48 Sanborn T A, Sleeper L A, Bates E R et al.. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK?.  J Am Coll Cardiol. 2000;  36 (3, Suppl A) 1123-1129
    CrossrefPubMedGoogle Scholar
  • 49 Thiele H, Sick P, Boudriot E et al.. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock.  Eur Heart J. 2005;  26 (13) 1276-1283
    CrossrefPubMedGoogle Scholar
  • 50 Burkhoff D, Cohen H, Brunckhorst C, O'Neill W W. TandemHeart Investigators Group . A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock.  Am Heart J. 2006;  152 (3) 469 e1-e8
    PubMedGoogle Scholar
  • 51 Seyfarth M, Sibbing D, Bauer I et al.. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction.  J Am Coll Cardiol. 2008;  52 (19) 1584-1588
    CrossrefPubMedGoogle Scholar
  • 52 Cheng J M, den Uil C A, Hoeks S E et al.. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials.  Eur Heart J. 2009;  30 (17) 2102-2108
    CrossrefPubMedGoogle Scholar
  • 53 Becker R C. Hemodynamic, mechanical, and metabolic determinants of thrombolytic efficacy: a theoretic framework for assessing the limitations of thrombolysis in patients with cardiogenic shock.  Am Heart J. 1993;  125 (3) 919-929
    CrossrefPubMedGoogle Scholar
  • 54 Hochman J S, Sleeper L A, White H D SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock et al. One-year survival following early revascularization for cardiogenic shock.  JAMA. 2001;  285 (2) 190-192
    CrossrefPubMedGoogle Scholar
  • 55 Dzavik V, Sleeper L A, Picard M H SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK Investigators et al. Outcome of patients aged > or = 75 years in the SHould we emergently revascularize Occluded Coronaries in cardiogenic shocK (SHOCK) trial: do elderly patients with acute myocardial infarction complicated by cardiogenic shock respond differently to emergent revascularization?.  Am Heart J. 2005;  149 (6) 1128-1134
    CrossrefPubMedGoogle Scholar
  • 56 White H D, Assmann S F, Sanborn T A et al.. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial.  Circulation. 2005;  112 (13) 1992-2001
    CrossrefPubMedGoogle Scholar
  • 57 Thompson C R, Buller C E, Sleeper L A et al.. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we use emergently revascularize Occluded Coronaries in cardiogenic shocK?.  J Am Coll Cardiol. 2000;  36 (3, Suppl A) 1104-1109
    CrossrefPubMedGoogle Scholar
  • 58 Antman E M, Anbe D T, Armstrong P W American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).  Circulation. 2004;  110 (5) 588-636
    CrossrefPubMedGoogle Scholar

Steven M HollenbergM.D. 

Cardiology and Critical Care Medicine, Cooper University Hospital, One Cooper Plaza

366 Dorrance, Camden, NJ 08103

Email: Hollenberg-Steven@cooperhealth.edu

      >